메뉴 건너뛰기




Volumn 12, Issue 4, 2014, Pages

A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma

(17)  Alimohamed, Nimira a   Lee, Jae Lyn b   Srinivas, Sandy c   Bjarnason, Georg A d   Knox, Jennifer J a   Mackenzie, Mary J e   Wood, Lori f   Vaishampayan, Ulka N g   Tan, Min Han h   Rha, Sun Young i   Donskov, Frede j   Tantravahi, Srinivas k   Kollmannsberger, Christian l   North, Scott m   Rini, Brian I n   Choueiri, Toni K o   Heng, Daniel Y C p  


Author keywords

Kidney cancer; Mammalian target of rapamycin; Sequencing; Treatment; Vascular endothelial growth factor

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

EID: 84904723067     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.12.003     Document Type: Article
Times cited : (22)

References (20)
  • 1
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 2
    • 62449186539 scopus 로고    scopus 로고
    • Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
    • B. Escudier, C. Szczylik, and T.E. Hutson et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
    • (2009) J Clin Oncol , vol.27 , pp. 1280-1289
    • Escudier, B.1    Szczylik, C.2    Hutson, T.E.3
  • 3
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 4
    • 56749161699 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
    • B.I. Rini, S. Halabi, and J.E. Rosenberg et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
    • (2008) J Clin Oncol , vol.26 , pp. 5422-5428
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 5
    • 77952300540 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
    • B. Escudier, J. Bellmunt, and S. Negrier et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
    • (2010) J Clin Oncol , vol.28 , pp. 2144-2150
    • Escudier, B.1    Bellmunt, J.2    Negrier, S.3
  • 6
    • 84867755853 scopus 로고    scopus 로고
    • Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial
    • (abstract 4501)
    • R.J. Motzer, D. Nosov, and T. Eisen et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial J Clin Oncol 30 Suppl 15 2012 (abstract 4501)
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 15
    • Motzer, R.J.1    Nosov, D.2    Eisen, T.3
  • 7
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 8
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase 3 trial
    • B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial Lancet 378 2011 1931 1939
    • (2011) Lancet , vol.378 , pp. 1931-1939
    • Rini, B.I.1    Escudier, B.2    Tomczak, P.3
  • 9
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial
    • R.J. Motzer, B. Escudier, and S. Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial Lancet 372 2008 449 456
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 10
    • 84876952724 scopus 로고    scopus 로고
    • Temsirolimus vs sorafenib as second-line therapy in metastatic renal cell carcinoma: Results from the INTORSECT trial
    • (Abstract LBA22-PR)
    • T. Hutson, B. Escudier, and E. Esteban et al. Temsirolimus vs. sorafenib as second-line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial Ann Oncol 23 suppl 9 2012 (Abstract LBA22-PR)
    • (2012) Ann Oncol , vol.23 , Issue.SUPPL. 9
    • Hutson, T.1    Escudier, B.2    Esteban, E.3
  • 11
    • 67349163859 scopus 로고    scopus 로고
    • Sequential sorafenib and sunitinib for renal cell carcinoma
    • M.P. Sablin, S. Negrier, and A. Ravaud et al. Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34
    • (2009) J Urol , vol.182 , pp. 29-34
    • Sablin, M.P.1    Negrier, S.2    Ravaud, A.3
  • 12
    • 58949092548 scopus 로고    scopus 로고
    • Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
    • A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
    • (2009) Cancer , vol.115 , pp. 61-67
    • Dudek, A.Z.1    Zolnierek, J.2    Dham, A.3    Lindgren, B.R.4    Szczylik, C.5
  • 13
    • 70349388719 scopus 로고    scopus 로고
    • Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    • B.I. Rini, G. Wilding, and G. Hudes et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
    • (2009) J Clin Oncol , vol.27 , pp. 4462-4468
    • Rini, B.I.1    Wilding, G.2    Hudes, G.3
  • 14
    • 78650383149 scopus 로고    scopus 로고
    • Temsirolimus in VEGF-refractory metastatic renal cell carcinoma
    • M.J. Mackenzie, B.I. Rini, and P. Elson et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2010 145 148
    • (2010) Ann Oncol , vol.22 , pp. 145-148
    • Mackenzie, M.J.1    Rini, B.I.2    Elson, P.3
  • 15
    • 78649568788 scopus 로고    scopus 로고
    • Sunitinib rechallenge in metastatic renal cell carcinoma patients
    • I.N. Zama, T.E. Hutson, and P. Elson et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 2010 5400 5406
    • (2010) Cancer , vol.116 , pp. 5400-5406
    • Zama, I.N.1    Hutson, T.E.2    Elson, P.3
  • 16
    • 77955470097 scopus 로고    scopus 로고
    • Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor targeted therapy
    • M.M. Vickers, T.K. Choueiri, and M. Rogers et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor targeted therapy Urology 76 2010 430 434
    • (2010) Urology , vol.76 , pp. 430-434
    • Vickers, M.M.1    Choueiri, T.K.2    Rogers, M.3
  • 17
    • 79960369634 scopus 로고    scopus 로고
    • Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy
    • (abstract 305)
    • D.Y. Heng, M. MacKenzie, and U.N. Vaishampayan et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy J Clin Oncol 29 Suppl 7 2011 (abstract 305)
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 7
    • Heng, D.Y.1    Mackenzie, M.2    Vaishampayan, U.N.3
  • 18
    • 73349084973 scopus 로고    scopus 로고
    • Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study
    • D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
    • (2009) J Clin Oncol , vol.27 , pp. 5794-5799
    • Heng, D.Y.1    Xie, W.2    Regan, M.M.3
  • 19
    • 37849001813 scopus 로고    scopus 로고
    • Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    • T.K. Choueiri, A. Plantade, and P. Elson et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
    • (2008) J Clin Oncol , vol.26 , pp. 127-131
    • Choueiri, T.K.1    Plantade, A.2    Elson, P.3
  • 20
    • 67651056360 scopus 로고    scopus 로고
    • Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
    • J.P. Dutcher, P. de Souza, and D. McDermott et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies Med Oncol 26 2009 202 209
    • (2009) Med Oncol , vol.26 , pp. 202-209
    • Dutcher, J.P.1    De Souza, P.2    McDermott, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.